Market Summary
Depression Screening Overview
As per MRFR analysis, the Depression Screening Market Size was estimated at 0.73 (USD Billion) in 2024. The Depression Screening Market Industry is expected to grow from 0.77 (USD Billion) in 2025 to 1.29 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.87% during the forecast period (2025 - 2034).
The growth of the depression screening market is attributed to the increasing prevalence of mental disorders, the rise in the adoption of new therapies and treatments, and the rising number of strategic initiatives.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review Depression Screening Trends
Increasing prevalence of mental disorders fuels market growth
The increasing prevalence of mental disorders across the globe is among the significant factors fueling the growth of the depression screening market. According to the World Health Organization (WHO), there has been a 13% increase in mental health conditions and other depressive disorders in the last decade. Similarly, according to the US Department of Health and Human Services (HHS), in 2020, it is estimated that 4.1 billion adolescents ages 12 and 17 had a major depressive episode, and 2.9 billion had a major depressive episode with severe impairment.
Therefore, the rising number of patients with related disorders is contributing to the growth in the global market. Additionally, several factors such as demographic changes, environmental conditions, and increasing mental stress are also resulting in rising mental health disorders, thereby fueling the market growth during the forecast period.
Depression Screening Segment Insights Depression Screening Indication Insights
The Depression Screening Market segmentation, based on indication, includes major depressive disorder, anxiety distress, bipolar disorder, psychotic disorders, and others. The major depressive disorder segment held the majority share in the market in 2022. Major Depressive Disorder (MDD) is a debilitating disease also referred to as unipolar depression or clinical depression. It occurs more frequently in women than in men. The factors that influence MDD are environmental factors (physical, emotional, and sexual abuse during the childhood period), disturbances in neurobiological stress-responsive systems, and family history. Furthermore, the COVID-19 pandemic also led to an increment in MDD globally owing to a surge in stress and anxiety caused by the fear of infection and lockdowns. For instance, in 2020, according to the Institute of Health Metrics and Evaluation, the global prevalence and burden of MDD in 204 countries and territories were 193 million, and additional cases of MDD due to COVID-19 were 53.2 million. Among the additional cases, there were 17.7 million males and 35.5 million females suffered from the disease. Females are disproportionately affected by MDD because they are more likely to be influenced by socioeconomic consequences, and children are also seen to be disproportionately affected, which increases the rate of depression, fueling the growth of the MDD segment.
Depression Screening Diagnosis Insights
The Depression Screening Market segmentation, based on diagnosis, includes psychological tests, blood tests, pharmacogenomic testing, and others. The psychological tests segment dominated the market in 2022. Psychological tests for depression include the Mood Disorder Questionnaire (MDQ), patient health questionnaire, Beck Depression Inventory (BDI), Zung self-rating depression scale (SDS), Centre for Epidemiologic Studies-depression scale (CES-D), Hamilton Rating Scale for Depression (HRSD), and others. The MDQ and hypomania checklist-32 (HCL-32) are utilized for the screening of bipolar disorder in primary care settings. Patient Health Questionnaire (PHQ) is used for MDD, in which PHQ-9 scores of 10 have a sensitivity of 88% and a specificity of 88% for MDD. The BDI indicates 0–9 for minimal depression, 10–18 for mild depression, 19–29 for moderate depression, and 30–63 for severe depression. SDS is mainly used for adults and is also convenient for identifying clinically depressive symptoms in the elderly. The CES-D scale ranges from 0 to 60, with higher scores indicating more depressive symptoms. The HRSD scale ranges from mild from 8–13, moderate from 14–18, severe from 19–22, and very severe >23.
Figure 2: Depression Screening Market, by Diagnosis , 2022 & 2032 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review Depression Screening End User Insights
The Depression Screening Market segmentation, based on end user, includes hospitals and clinics, home-based, and research and academic institutes. The hospitals and clinics segment dominated the market in 2022. Hospitals and clinics use a general screening tool that is full of PHQ-9, which is standard practice for physicians, nurse practitioners, and licensed behavioral health providers. It has been shown in several studies that hospitals and clinics mostly use this test to improve health services, provide quality care, and improve health outcomes for medically underserved populations discharged from the hospital.
Depression Screening Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. The North America depression screening market accounted for the largest market share in 2022. Key factors attributed to its large share include developed healthcare infrastructure, increasing technological advancement regarding mental health, and the presence of many market players in the region. For instance, in November 2020, Janssen Pharmaceutical (US) announced its collaboration with Koa Health (US) to provide cost-effective digital treatment for depression-suffering patients and various therapies to strengthen its position in the global market. In addition, the easy availability of advanced diagnostics is also contributing to regional market growth. The rapid growth of the depression screening industry in the US coupled with technological advancements in the depression screening industry provides continuous progress in the field of mental health.
Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DEPRESSION SCREENING MARKET BY REGION 2022 & 2032 (USD Billion) 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe depression screening market accounted for the second-largest market share due to growing prevalence of different types of depressive disorders amongst individuals, and the rising awareness of treating these depressive diseases. Furthermore, the Germany depression screening market is attributed to hold the largest market share, and the France depression screening market is projected be the fastest growing market in the Europe region.
The Asia-Pacific depression screening market is expected to be the fastest growing from 2023 to 2032 due to increase in disposable income of individuals, increasing funds in research activities, and rising prevalence of mental disorders. Moreover, China depression screening market accounted to hold the largest market share, and the India depression screening market is projected to be the fastest growing market in the Asia-Pacific region.
Depression Screening Key Market Players & Competitive Insights
The Depression Screening Market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.
The business model developed by manufacturers in the Depression Screening Market includes manufacturing high-quality pharmaceutical products. Mergers and collaborations were also observed to expand the company's product portfolio, as well as introduce new products. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. Key manufacturers in the depression screening market are focusing on developing drugs with advanced technologies. It is also projected that rising global R&D initiatives and healthcare expenditure will boost the market's growth in the upcoming future.
Medtronic (Ireland) is a global healthcare solutions company committed to improving people's lives through medical technologies, services, and solutions. With Covidien, the company has accelerated and advanced its ability to create meaningful innovations for hospitals, health systems, and healthcare providers to deliver the best care possible to patients and their families worldwide. The company's businesses majorly fall into four groups the Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group, and the Minimally Invasive Therapies Group (MITG). It operates in over 370 locations across almost 150 countries. Medtronic has been awarded more than 4,600 patents.
Moreover, In August 2022, Medtronic (Ireland) launched SenSight directional lead system for deep brain stimulation therapy in India.
Key Companies in the depression screening market includes.
- National Psychological Corporation (India)
- Bruker (US)
- Medtronic (Ireland)
- Multi-Health Systems Inc. (US)
- Nedley Health (US)
- Danaher Corporation (US)
- Pearson (UK)
- SIGMA Assessment Systems Inc. (UK)
- Siemens (Ireland)
- Psychological Assessment Resources, Inc. (US)
Depression Screening Industry Developments
- In June 2022, Bruker (US) launched enhanced 3d holographic stimulation for optogenetics on its ultima 2pplus multiphoton microscope.
- In November 2021, Siemens (Ireland) introduced Magnetom Free. It is a cost-effective whole-body MRI scanner designed to enable significantly better access to magnetic resonance imaging.
- In November 2019, Siemens (Ireland) introduced a new Somatom X.cite CT scanner with a revolutionary user guidance system.
Depression Screening Segmentation Depression Screening Indication Outlook
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
Depression Screening Diagnosis Outlook
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
Depression Screening End User Outlook
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
Depression Screening Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Market Size & Forecast
| Attribute/Metric | Details |
|
Market Size 2024 |
0.73 (USD Billion) |
|
Market Size 2025 |
0.77 (USD Billion) |
|
Market Size 2034 |
1.29 (USD Billion) |
|
Compound Annual Growth Rate (CAGR) |
5.87 % (2025 - 2034) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Base Year |
2024 |
|
Market Forecast Period |
2025 - 2034 |
|
Historical Data |
2020 - 2024 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Indication, Diagnosis, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | National Psychological Corporation (India), Bruker (US), Medtronic (Ireland), Multi-Health Systems Inc. (US), Nedley Health (US), Danaher Corporation (US), Pearson (UK), SIGMA Assessment Systems Inc. (UK), Siemens (Ireland), and Psychological Assessment Resources, Inc. (US) |
| Key Market Opportunities | · Increasing technological advancement regarding mental health |
| Key Market Drivers | · Increasing prevalence of mental disorders · Rise in adoption of new therapies and treatments · Rising number of strategic initiatives |
Major Players
Depression Screening Market Segmentation
Depression Screening Indication Outlook (USD Billion, 2019-2032)
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
Depression Screening Diagnosis Outlook (USD Billion, 2019-2032)
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
Depression Screening End User Outlook (USD Billion, 2019-2032)
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
Depression Screening Regional Outlook (USD Billion, 2019-2032)
-
North America Outlook (USD Billion, 2019-2032)
-
North America Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
North America Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
North America Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- US Outlook (USD Billion, 2019-2032)
-
US Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
US Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
US Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Canada Outlook (USD Billion, 2019-2032)
-
Canada Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Canada Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Canada Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
-
Europe Outlook (USD Billion, 2019-2032)
-
Europe Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Europe Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Europe Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Germany Outlook (USD Billion, 2019-2032)
-
Germany Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Germany Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Germany Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- France Outlook (USD Billion, 2019-2032)
-
France Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
France Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
France Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- UK Outlook (USD Billion, 2019-2032)
-
UK Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
UK Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
UK Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Italy Outlook (USD Billion, 2019-2032)
-
Italy Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Italy Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Italy Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Spain Outlook (USD Billion, 2019-2032)
-
Spain Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Spain Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Spain Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Rest of Europe Outlook (USD Billion, 2019-2032)
-
Rest of Europe Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Rest of Europe Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Rest of Europe Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
-
Asia-Pacific Outlook (USD Billion, 2019-2032)
-
Asia-Pacific Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Asia-Pacific Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Asia-Pacific Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- China Outlook (USD Billion, 2019-2032)
-
China Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
China Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
China Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Japan Outlook (USD Billion, 2019-2032)
-
Japan Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Japan Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Japan Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- India Outlook (USD Billion, 2019-2032)
-
India Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
India Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
India Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- South Korea Outlook (USD Billion, 2019-2032)
-
South Korea Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
South Korea Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
South Korea Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Australia Outlook (USD Billion, 2019-2032)
-
Australia Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Australia Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Australia Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)
-
Rest of Asia-Pacific Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Rest of Asia-Pacific Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Rest of Asia-Pacific Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
-
Rest of the World Outlook (USD Billion, 2019-2032)
-
Rest of the World Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Rest of the World Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Rest of the World Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Middle East Outlook (USD Billion, 2019-2032)
-
Middle East Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Middle East Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Middle East Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Africa Outlook (USD Billion, 2019-2032)
-
Africa Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Africa Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Africa Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
- Latin America Outlook (USD Billion, 2019-2032)
-
Latin America Depression Screening by Indication
- Major Depressive Disorder
- Anxiety Distress
- Bipolar Disorder
- Psychotic Disorders
- Others
-
Latin America Depression Screening by Diagnosis
- Psychological Tests
- Blood Tests
- Pharmacogenomic Testing
- Others
-
Latin America Depression Screening by End User
- Hospitals and Clinics
- Home-based
- Research and Academic Institutes
-
Rest of the World Depression Screening by Indication
-
Asia-Pacific Depression Screening by Indication
-
Europe Depression Screening by Indication
-
North America Depression Screening by Indication
Leave a Comment